GlassScriptPhysician profile
Karen R Konz
NPI 1477503670
$3,874.69
in general payments reported to CMS, 2019-2025
19 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $165 · 2021: $573 · 2022: $701 · 2023: $617 · 2024: $779 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.58 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,746.82 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $727.86 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $250.56 | 2019-2025 | |
| Amgen INC. | $197.29 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $140.19 | 2023-2025 | |
| Optinose US, INC. | $119.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $111.40 | 2019-2022 | |
| Kaleo, INC. | $97.07 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $78.03 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.09 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $62.83 | 2020-2024 | Xolair |
| Biocryst US Sales Co., LLC | $60.05 | 2022-2024 | Orladeyo |
| Csl Behring | $41.55 | 2025 | Andembry |
| Cycle Pharmaceuticals INC | $39.36 | 2025 | Sajazir |
| Takeda Pharmaceuticals U.S.A., INC. | $37.13 | 2025 | Eohilia, Takhzyro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $28.03 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Pfizer INC. | $24.28 | 2019-2020 | |
| Grifols USA, LLC | $18.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Konz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.